An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy - Report - MDSpire
Advertisement
An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy
Clinical Report: Prognostic Model Utilizing LDH in ES-SCLC Patients
Overview
Expand on the significance of consolidative thoracic radiation in the treatment regimen.
Background
Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by rapid progression and poor survival rates despite treatment advancements. Traditional prognostic factors have limited utility, highlighting the need for reliable biomarkers. Serum LDH has emerged as a potential indicator of tumor burden and prognosis in various malignancies, including ES-SCLC.
Data Highlights
Parameter
Value
Number of patients
81
Hazard ratio for LDH
1.006 per 1 U increase
12-month AUC for OS
0.731
24-month AUC for OS
0.694
Key Findings
Serum LDH is independently associated with poorer overall survival in ES-SCLC (HR 1.006 per 1 U increase, p < 0.001).
Patients with elevated LDH levels (>250 U/L) have significantly reduced overall survival compared to those with lower levels (≤250 U/L; p=0.0012).
The prognostic nomogram incorporating LDH, AJCC stage, SII, and immunotherapy status demonstrated moderate discriminative ability.
High pretreatment LDH levels correlate with significantly shorter survival in ES-SCLC patients.
Integration of LDH into clinical practice may enhance personalized management strategies for ES-SCLC.
Clinical Implications
Clinicians should consider serum LDH levels as a key prognostic factor when evaluating treatment strategies for patients with ES-SCLC. The developed nomogram can assist in risk stratification and inform personalized treatment approaches in the context of chemo-immunotherapy.
Conclusion
Serum LDH serves as a valuable prognostic marker for overall survival in ES-SCLC patients receiving combined therapies, and the nomogram developed may aid in clinical decision-making.
